PRESS RELEASE: Amarin Corporation (Zelapar - Parkinson's) to Present at Friedland Capital's Biotech, Medical And Healthcare Con

[Murray Charters <mcharters@xxxxxxxxxxxxxx>]

Amarin Corporation to Present at Friedland Capital's Biotech, Medical And 
Healthcare Conference
Tuesday September 23, 9:01 am ET

LONDON, Sept. 23 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN 
- News; "Amarin") announced today that
it would participate in Friedland Capital's Biotech, Medical and Healthcare 
Conference. A presentation will be made by
Rick Stewart, Chief Executive Officer on September 24, 2003 at 9.20 a.m. EDT at 
The Harvard Club of New York.

This conference, including Amarin's presentation, will be simultaneously audio 
webcast "live" and after the conference
the audio webcast will be archived at: 


Amarin Corporation plc is a specialty pharmaceutical company focused on 
neurology. The Company plans to become a leader
in these therapeutic categories by providing innovative products and solutions 
that address significant unmet medical
needs. Amarin has eleven pharmaceutical products on the US market along with a 
development pipeline that includes two
late-stage candidates: Zelapar(TM) (selegiline orally disintegrating tablets), 
for Parkinson's disease and LAX-101, a
proprietary compound for Huntington's Disease.

For press releases and other corporate information, visit our website at 


Statements in this press release that are not historical facts are 
forward-looking statements that involve risks and
uncertainties which may cause the Company's actual results in future periods to 
be materially different from any
performance suggested herein. Such risks and uncertainties include, without 
limitation, risks associated with the
inherent uncertainty of pharmaceutical research, product development and 
commercialisation, the impact of competitive
products and patents, as well as other risks and uncertainties detailed from 
time to time in periodic reports. For more
information, please refer to Amarin Corporation's Annual Report for 2002 on 
Form 20-F and its Form 6-Ks as filed with
the U.S. Securities and Exchange Commission. The Company assumes no obligation 
to update information on its
expectations.

Source: Amarin Corporation plc

SOURCE:  PR Newswire / Yahoo News (press release)


* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:listserv@xxxxxxxxxxxxxxxxxxxx
In the body of the message put: signoff parkinsn